厄貝沙坦與厄貝沙坦/氫氯噻嗪復(fù)方制劑治療輕中度原發(fā)性高血壓的療效對比觀察(2)
總之,對于在社區(qū)就診的輕中度原發(fā)性高血壓患者,厄貝沙坦/氫氯噻嗪復(fù)方制劑治療降壓療效滿意,達(dá)標(biāo)率高,且安全,不良反應(yīng)少,是輕中度高血壓患者的理想用藥。
[參考文獻(xiàn)]
[1] Hansson L,Zanchetti A,Carruthers SG,et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT)randomised trial[J]. Lancet,1998,351(9118):1755-1762.
[2] 孫寧玲,荊珊,陳捷. 厄貝沙坦/氫氯噻嗪復(fù)方片劑治療中國高血壓病患者的達(dá)標(biāo)率分析[J]. 中華心血管病雜志,2005,33(7):618-621.
[3] 陳少萍,鄭興,秦永文. 復(fù)方厄貝沙坦治療原發(fā)性高血壓的療效觀察[J]. 第二軍醫(yī)大學(xué)學(xué)報(bào),2005,26(4):164-166.
[4] 國高血壓防治指南修訂委員會. 中國高血壓防治指南[J]. 中華高血壓雜志,2011,19(8):701-743.
[5] European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology. Guidelines for the management of arterial hypertension[J]. J Hypertens,2003,21(6):1011-1053.
[6] Julius S,Kjeldsen SE,Weber M,et al. Outcomes in hypertensives patients a high cardiovascular risk treated with regimen based on valsartan OR amlodipine the value randomized trial[J]. Lancet,2004,363(9426):2022-2031.
[7] Watchell K,Hornesstam B,Lehto M,et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation:The Losartan Intervention For End Point Reduction in Hypertension(LIFE) study[J]. JACC,2005,45(5):705-711.
[8] Franse LV,Pahor M,Bari MD,et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertensionin the Elderly Program [J]. Hypertension,2002,35(5):1025-1030.
(收稿日期:2012-05-10 本文編輯:趙麗萍), http://www.www.srpcoatings.com(趙鳳梅 王成桓 肖燕蘭)
[參考文獻(xiàn)]
[1] Hansson L,Zanchetti A,Carruthers SG,et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT)randomised trial[J]. Lancet,1998,351(9118):1755-1762.
[2] 孫寧玲,荊珊,陳捷. 厄貝沙坦/氫氯噻嗪復(fù)方片劑治療中國高血壓病患者的達(dá)標(biāo)率分析[J]. 中華心血管病雜志,2005,33(7):618-621.
[3] 陳少萍,鄭興,秦永文. 復(fù)方厄貝沙坦治療原發(fā)性高血壓的療效觀察[J]. 第二軍醫(yī)大學(xué)學(xué)報(bào),2005,26(4):164-166.
[4] 國高血壓防治指南修訂委員會. 中國高血壓防治指南[J]. 中華高血壓雜志,2011,19(8):701-743.
[5] European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology. Guidelines for the management of arterial hypertension[J]. J Hypertens,2003,21(6):1011-1053.
[6] Julius S,Kjeldsen SE,Weber M,et al. Outcomes in hypertensives patients a high cardiovascular risk treated with regimen based on valsartan OR amlodipine the value randomized trial[J]. Lancet,2004,363(9426):2022-2031.
[7] Watchell K,Hornesstam B,Lehto M,et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation:The Losartan Intervention For End Point Reduction in Hypertension(LIFE) study[J]. JACC,2005,45(5):705-711.
[8] Franse LV,Pahor M,Bari MD,et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertensionin the Elderly Program [J]. Hypertension,2002,35(5):1025-1030.
(收稿日期:2012-05-10 本文編輯:趙麗萍), http://www.www.srpcoatings.com(趙鳳梅 王成桓 肖燕蘭)